Background
==========

Lung cancer is the most common cause of cancer-related death with an overall 5-year survival rate of 16% \[[@B1]\]. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung carcinomas and is frequently diagnosed in an advanced stage \[[@B2]\]. First-line treatment of advanced NSCLC typically consists of platinum-based chemotherapy \[[@B3],[@B4]\]. Only a minority of patients respond to this treatment, at the cost of substantial toxicity for all treated patients \[[@B5]\]. There is an urgent need for methods enabling outcome prediction in order to select patients likely to benefit from treatment.

The serum peptidome, that comprises peptides and proteins with a molecular weight of less than 10 kDa, represents a dynamic reflection of tissue function in health and disease \[[@B6]\]. Mass spectrometry (MS) is increasingly used to profile the serum peptidome \[[@B7]-[@B9]\]. Peaks in the serum peptide spectra correspond to peptide ions, with the amplitude of the peaks indicative of relative abundance \[[@B10]\]. Magnetic bead-assisted serum peptide capture coupled to matrix assisted laser desorption/ionization time-of-flight MS (MALDI-TOF-MS) is a serum peptide profiling strategy gaining in popularity compared to surface-enhanced laser desorption/ionization (SELDI)-based platforms due to superior resolution of MALDI instruments, the possibility to obtain structural (MS/MS) information of signature peptides and superior binding capacity of the magnetic beads compared to a flat SELDI-chip surface \[[@B11]\].

Here we report on a MALDI-TOF-MS dataset of serum samples from advanced NSCLC patients, who were treated with first-line chemotherapy, consisting of cisplatin and gemcitabine, as well as bortezomib, in a previously reported prospective clinical trial \[[@B12]\]. The efficacy of cisplatin-gemcitabine alone is limited, a partial tumor response being achieved in about one third of NSCLC patients and with a median progression free survival of four to five months \[[@B13]\]. Preclinical as well as initial clinical studies suggested combining cisplatin-gemcitabine with proteasome inhibitor bortezomib might enhance efficacy \[[@B14]-[@B17]\].

We hypothesized that specific serum peptidome patterns could predict clinical outcome of patients who underwent chemotherapy-based treatment. For this purpose, data analyses of serum peptide profiles were conducted. Our primary aim was to establish serum peptide signatures that could predict positive or negative clinical outcome upon treatment. Clinical endpoints used to establish these signatures were response to treatment according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, as well as progression-free survival duration of treated patients. Furthermore, in a secondary analysis, we compared the serum peptide profiles of treated patients with those obtained from cancer-free control subjects in an initial attempt to establish cancer-specific serum peptide patterns.

Results
=======

Pre-treatment serum peptide patterns of NSCLC patients
------------------------------------------------------

First, pre-treatment serum spectra of 27 NSCLC patients were determined. See Table [1](#T1){ref-type="table"} for patient characteristics. Six hundred eighty-two peaks could be distinguished. The intra-run and inter-run coefficients of variance were 16% and 18%, respectively.

###### 

Patient characteristics

  ------------------------------------------------------------------
                                               **NSCLC patients**\
                                               **(n = 27)**
  -------------------------------------------- ---------------------
  *Age, years*                                 

   Median                                      53

   Range                                       35-67

  *Sex, n (%)*                                 

   Male                                        15 (55.6)

   Female                                      12 (44.4)

  *Stage, n (%)*                               

   IIIB                                        5 (18.5)

   IV                                          22 (81.5)

  *Histology, n (%)*                           

   Squamous cell carcinoma                     6 (22.2)

   Adenocarcinoma                              12 (44.4)

   Adenosquamous cell carcinoma                2 (7.4)

   Undifferentiated non-small cell carcinoma   7 (25.9)

  *Karnofski performance status, n (%)*        

   70                                          4 (14.8)

   80                                          10 (37.0)

   90                                          8 (29.6)

   100                                         5 (18.5)

  *Smoking history, n (%)*                     

   No                                          1 (3.7)

   Current or former                           26 (96.3)

  *RECIST, n (%)*                              

   Partial response                            9 (33.3)

   Stable disease                              15 (55.6)

   Progressive disease                         3 (11.1)

  *Survival, days*                             

   Median progression-free survival            152

   Median overall survival                     315
  ------------------------------------------------------------------

Time-course analysis
--------------------

We first looked for peptides that exhibited significant changes in intensity level in three time points: (1) pre-treatment (preTx), (2) after two cycles of treatment (Post-2), and (3) at the end of treatment (EOT). Forty-four peaks were determined as significant (Table [2](#T2){ref-type="table"}). The spectra overlay of the top 8 peaks is illustrated in Figure [1](#F1){ref-type="fig"}. Note that for example the peak at *m/z*2567.3659 has a higher intensity at end of treatment (green) compared to pre-treatment (red) and the peak at *m/z*1561.7288 has a lower intensity at end of treatment compared to pre-treatment.

![**Comparison serum profiles time course**. Top 8 differential peaks that exhibit changes over the three time points: pre-treatment (PreTx) (red), after two cycles of treatment (Post-2) (blue), and at end of treatment (EOT) (green). Eight peaks randomly selected out of the remaining 638 peaks. Each overlay contains spectra with normalized intensities.](1477-5956-7-34-1){#F1}

###### 

Comparison serum profiles time-course

  ***m/z***   **p-value**   **peptide ID**
  ----------- ------------- ----------------
  904.4726    0.00054514    BK
                            
  1129.4849   0.0013845     FPB
                            
  1183.5995   0.0094174     
                            
  1201.5663   0.0045301     
                            
  1263.5958   0.0024011     FPA
                            
  1288.6006   0.0013845     
                            
  1347.5297   0.047967      
                            
  1350.6275   0.0013845     FPA
                            
  1389.6433   0.0013845     
                            
  1402.671    0.0089624     
                            
  1418.539    0.026155      
                            
  1432.644    0.039554      
                            
  1440.5407   0.011867      
                            
  1445.5828   0.0032159     
                            
  1447.6855   0.005355      
                            
  1450.4893   0.024048      
                            
  1456.5093   0.039554      
                            
  1458.4946   0.020271      
                            
  1460.6257   0.0022586     
                            
  1477.6539   0.010181      
                            
  1479.6646   0.005355      
                            
  1487.6226   0.0017206     
                            
  1491.6634   0.0074232     
                            
  1501.748    0.011         
                            
  1503.5994   0.0087051     
                            
  1507.6643   0.0024697     
                            
  1536.6906   0.0087051     FPA
                            
  1552.669    0.003822      Glu-FBP
                            
  1561.7288   0.00048292    
                            
  1569.6823   0.0014303     
                            
  1573.7005   0.0022586     
                            
  1616.6366   0.013817      P-FPA
                            
  1630.6679   0.0022586     
                            
  1670.5947   0.011876      
                            
  1690.9254   0.03325       C3f
                            
  1777.966    0.0087051     C3f
                            
  1865.0022   0.011         C3f
                            
  2494.1536   0.030814      
                            
  2567.3659   0.00032806    seAlb
                            
  2602.3048   0.019183      CF XIIIA
                            
  2743.4663   0.005355      
                            
  2747.4349   0.0014303     
                            
  2789.0914   0.037043      
                            
  3156.6207   0.020803      ITIH4

In NSCLC patients, 44 peaks were significantly differential over the three time points: pre-treatment, after two cycles of treatment and end of treatment. Ordered by *m/z*value. Abbreviations: BK: bradykinin; FBP: fibrinopeptide B; FPA: fibrinopeptide A; Glu-FPB: Glu-1-fibrinopeptide B; P-FPA: phospho-fibrinopeptide A; C3f: complement C3 f; seAlb: serum albumen; CFXIIIA: coagulation factor XIIIA; ITIH4: inter-alpha-trypsin inhibitor heavy chain H4.

Analysis of the clinical outcome: progression-free survival
-----------------------------------------------------------

The patients were divided into two subsets according to PFS duration. Of the 27 NSCLC patients, 11 patients with the shortest PFS were nominated as \"short PFS\" group (PFS ≤ 127 days), 11 patients with the longest PFS were nominated as \"long PFS\" group (PFS ≥ 178 days). Four patients with PFS duration around the median PFS (152 days) were excluded from the analysis. A fifth patient was excluded who had a partial response but died 36 days after start of treatment due to a cause not likely due to tumor progression \[[@B12]\].

Six differentially expressed peptides between the two groups were detected (see Figure [2A](#F2){ref-type="fig"} and Table [3](#T3){ref-type="table"}). Median intensity of all six peptides was higher in the \"short PFS\" group compared to the \"long PFS\" group. This 6-peptide signature was used to retrospectively divide the total study population (n = 27) into a predicted \"short PFS\" group and a predicted \"long PFS\" group. Median PFS was significantly shorter at 120 days (95% CI 54-186 days) in patients predicted to have a short PFS vs. 191 days (95% CI 154-228 days) in patients predicted to have a long PFS (p-value: 0.036). Median overall survival (OS) of patients predicted to have short PFS vs. long PFS was 144 days (95% CI 75-213 days) vs. 436 days (95% CI 292-580 days) (p-value: 0.036) (Figure [2B](#F2){ref-type="fig"}). For the OS analyses, two patients were censored at last known date to be alive.

###### 

Comparison serum profiles short PFS vs. long PFS

  ***m/z***   **p-value**
  ----------- --------------
  2489.3052   0.018082
              
  2318.2202   0.030239
              
  2209.0934   0.041789\*\*
              
  2215.2849   0.041789
              
  2376.2096   0.041789
              
  1545.616    0.048844

Six peaks were significantly differential comparing NSCLC patients with short progression-free survival and long progression-free survival. All peaks were up-regulated in the group with short progression-free survival. None of the six peaks were positively identified. Ordered by p-value. \*\* identified by Tempst *et al.*as high-molecular-weight kininogen \[[@B19]\].

![**Comparison serum profiles short PFS vs. long PFS**. **A**, six peaks are differential between the two groups: short PFS (red) and long PFS (blue). Six randomly selected peaks. Each overlay contains spectra with normalized intensities. **B**, Kaplan-Meier (1) time to progression and (2) overall survival curve in NSCLC patients, by prediction of short or long PFS using the 6-peptide signature (intent-to-treat population, n = 27). **C**, median of the seven differential peaks comparing short PFS (red) and long PFS (blue) over the three time points: pre-treatment (PreTx), after two cycles of treatment (Post-2), and at end of treatment (EOT) (Y-axis: intensity).**D**, Kaplan-Meier (1) time to progression and (2) overall survival curve in NSCLC patients, by prediction of short or long PFS using the 13-peptide signature (intent-to-treat population, n = 27).](1477-5956-7-34-2){#F2}

When considering also Post-2 and EOT samples, we found seven differential peptides distinguishing the clinical groups (see Figure [2C](#F2){ref-type="fig"} and Table [4](#T4){ref-type="table"}). These peptides do not overlap with peptides from the pre-treatment signature. Using the combined 13-peptide signature to classify the total study population, median PFS was significantly shorter at 120 days (95% CI 70-170 days) in patients predicted to have a short PFS vs. 199 days (95% CI 181-217 days) in patients predicted to have a long PFS (p-value: \< 0.001). Median overall survival of patients predicted to have short vs. long PFS was 144 days (95% CI 96-192 days) vs. 478 days (95% CI 203-753 days) (p-value: 0.002) (Figure [2D](#F2){ref-type="fig"}).

###### 

Comparison time-course serum profiles short PFS vs. long PFS

  ***m/z***   **p-value**   **peptide ID**
  ----------- ------------- ----------------
  3215.1939   0.0021001     
                            
  1616.6366   0.010132      P-FPA
                            
  1292.4157   0.013272      
                            
  1418.539    0.013272      
                            
  1596.189    0.022018      
                            
  1440.5407   0.043474      
                            
  1670.5947   0.044759      

Seven peaks were significantly differential comparing NSCLC patients with short progression-free survival and long progression-free survival, using three time points: pre-treatment, after two cycles of treatment and end of treatment. Ordered by p-value.

Abbreviation: P-FPA: phospho-fibrinopeptide A.

Finally, we carried out classification analysis using support vector machine. Using all 682 peptides, the LOOCV accuracy was very poor, at about 50%. When the six differential pre-treatment peptides were used, the LOOCV accuracy was 82% with both 82% sensitivity and 82% specificity. Selecting six different peptides randomly resulted in an average accuracy of 68% (10 runs). The LOOCV prediction accuracy improved when we used also the seven peptides that changed differently in intensity level over the three time points. Here, using the 13 peptides we could separate the two groups with a LOOCV accuracy of 86% at 100% sensitivity and 73% specificity (the average accuracy over 10 runs with random selection of 13 peptides was 71%).

Analysis of the clinical outcome: tumour response
-------------------------------------------------

To identify a signature associated with tumour response, we divided the patients into three groups according to tumour response following treatment: (1) partial response (PR), (2) stable disease (SD), (3) progressive disease (PD), as defined by RECIST \[[@B18]\]. Because there were only three patients with progressive disease, we created two groups: PR and SD/PD combined (\"no PR\"). The first group had 9 patients, and the second group consisted of 18 patients.

Comparing pre-treatment samples, we detected five differential peaks (see Figure [3A](#F3){ref-type="fig"} and Table [5](#T5){ref-type="table"}). Of the five peptides, two were also present in the list of differential peaks comparing short PFS and long PFS (*m/z*= 2215.2849 and 2318.2202). The 5-peptide signature was used to retrospectively divide the total patient population in a PR vs. no PR group (n = 27). In the patient group classified as no PR, median PFS was significantly shorter at 125 days (95% CI 115-135 days) vs. 231 days (95% CI 85-377 days) in the group classified as PR (p-value: 0.003). Median overall survival of patients predicted to have no PR was shorter, but not significantly, at 231 days (95% CI 41-421 days) vs. 478 days (95% CI 120-836 days) for patients predicted to have a PR (p-value: 0.073) (Figure [3B](#F3){ref-type="fig"}).

![**Comparison serum profiles PR vs. no PR**. **A**, five differential peaks in the comparison between PR (red) versus PD+SD (blue) using pre-treatment samples. Five randomly selected in the same comparison. Each overlay contains spectra with normalized intensities. **B**, Kaplan-Meier (1) time to progression and (2) overall survival curve in NSCLC patients, by prediction of PR or no PR, using the 5-peptide signature (intent-to-treat population, n = 27). **C**, median of the five differential peaks in the comparison between PR (red) versus PD+SD (blue) using three time points: pre-treatment (PreTx), after two cycles of treatment (Post-2), and at end of treatment (EOT). **D**, Kaplan-Meier (1) time to progression and (2) overall survival curve in NSCLC patients, by prediction of PR or no PR, using the 10-peptide signature (intent-to-treat population, n = 27).](1477-5956-7-34-3){#F3}

###### 

Comparison serum profiles PR vs. no PR

  ***m/z***   **p-value**
  ----------- -------------
  2215.2849   0.0083178
              
  2009.0039   0.015663
              
  2318.2202   0.032445
              
  2378.1982   0.042583
              
  900.4258    0.048584

Five peaks were significantly differential comparing NSCLC patients with a partial response versus patients with stable or progressive disease. None of the 5 peptides were positively identified. Ordered by p-value.

Next we included also the Post-2 and EOT samples, resulting in five additional differential peptides (see Figure [3C](#F3){ref-type="fig"} and Table [6](#T6){ref-type="table"}). Again, there was no overlap between these five peptides and the peptides found when using the pre-treatment samples only. However, of these five peptides, three peptides were also in the list of significant peptides when comparing short PFS and long PFS over the three time points (*m/z*= 1596.189, 1616.637 and 3215.194). The 10-peptide signature was used to retrospectively divide the total patient population in PR vs. no PR (n = 27). In the patient group classified as no PR, median PFS was 125 days (95% CI 91-159 days) vs. 231 days (95% CI 117-345 days) in the group classified as PR (p-value 0.038). Median overall survival of patients predicted to have no PR was shorter, but not significantly, at 231 days (95% CI 36-426 days) vs. 613 days (95% CI 0-1253 days) for patients predicted to have a PR (p-value: 0.077) (Figure [3D](#F3){ref-type="fig"}).

###### 

Comparison time-course serum profiles PR vs. no PR

  ***m/z***   **p-value**   **peptide ID**
  ----------- ------------- ----------------
  1616.6366   0.007392      P-FPA
                            
  1596.189    0.011159      
                            
  872.4325    0.018308      
                            
  3215.1939   0.028873      
                            
  1631.2111   0.040931      

Five peaks were significantly differential comparing NSCLC patients with a partial response versus patients with stable or progressive disease, using three time points: pre-treatment, after two cycles of treatment and end of treatment. Ordered by p-value.

Abbreviation: P-FPA: phospho-fibrinopeptide A

Classification analysis was performed using support vector machine with different combinations of features. The LOOCV accuracy was again poor when using all 682 peptides, at about 67%. When the five differential pre-treatment peptides were used, the LOOCV accuracy was 89% at 100% sensitivity and 83% specificity. The average accuracy over 10 runs was 74% using random feature selection for five peptides. The LOOCV prediction accuracy was reduced to 85%, at 100% sensitivity and 78% specificity, when we used also the five peptides that changed differently in intensity level over the three time points (Figure [4](#F4){ref-type="fig"} provides an overview of the study and study results).

![**Study flowchart**. Serum profiling was performed in 27 NSCLC patients. \"Feature list 1\" represents total number of features before intensity and statistical filters. For each comparison, \"Feature list 2\" represents the number of differential peptide ions comparing pre-treatment sera (white filled circle), time-course sera (black filled circle) and pre-treatment plus time-course combined (grey filled circle). Accuracy (ac), sensitivity (sn) and specificity (sp) of algorithms are indicated. SVM: support vector machine; LOOCV: leave-one-out-cross validation; pts: patients.](1477-5956-7-34-4){#F4}

Peptide pattern discriminating NSCLC patients from cancer-free controls
-----------------------------------------------------------------------

Finally, in an exploratory additional analysis, we compared the serum peptide spectra of 13 cancer-free control subjects (median age: 38 years old; range: 27-58 years old) and the pre-treatment serum spectra of the 27 NSCLC patients included in this study. We performed a principal component analysis (PCA) analysis of the 40 profiles using all 682 peptides, see Figure [5A](#F5){ref-type="fig"}. While there is overlap between the two groups in the three dimensional plot, the healthy profiles (in red) are clustered at the bottom right region. Furthermore, we observed no indication of outliers in the dataset. Next we performed a supervised analysis to identify peptides that were significantly differential in intensity between the two groups. For this purpose, the Mann-Whitney U test was carried out on each of the 682 peptides using all profiles. The peptides were selected based on the criteria outlined in Methods, resulting in 47 peptides. A heat map of the intensities of the 47 peptides is shown in Figure [5B](#F5){ref-type="fig"} (see also Table [7](#T7){ref-type="table"}). Figure [5C](#F5){ref-type="fig"} shows the spectra overlay of the top 8 most discriminating peaks, all of which have a p-value \< 0.0001. Note that for example the peak at m/z 1777.966 has a higher intensity in NSCLC patients (blue) compared cancer-free controls (red) and the peak at m/z 1039.6249 has a lower intensity in NSCLC patients. We carried out classification analysis using support vector machine. A grid search for parameters was employed to find the best model according to LOOCV. Using all 682 peptides, an LOOCV accuracy of 93% was achieved. When the 47 peptides selected by the Mann-Whitney U test were used, the LOOCV accuracy was 98% with 100% sensitivity and 96% specificity. To substantiate the result, we compared it to a random selection of peptides. Using the same model selection mechanism for support vector machine with 47 different peptides randomly selected the average accuracy over 10 runs was 90%.

![**Comparison serum profiles NSCLC vs. cancer-free controls**. **A**, Principle Component Analysis (PCA) NSCLC vs. cancer-free control comparison. **B**, heat map of the 47 differential peaks. The peaks are ordered by median fold change between the two groups. **C**, spectra overlay of the 8 most differential peaks in the healthy (red) versus NSCLC (blue) comparison. Spectra overlay of the 8 peaks randomly selected out of the remaining 635 peptides.](1477-5956-7-34-5){#F5}

###### 

Comparison serum profiles NSCLC vs. cancer-free controls

  ***m/z***   **p-value**   **peptide ID**
  ----------- ------------- ----------------
  1777.966    2.18E-06      C3f
                            
  1877.9926   9.96E-06      
                            
  1545.616    2.49E-05      
                            
  1690.9254   2.83E-05      C3f
                            
  1865.0022   2.83E-05      C3f
                            
  1039.6249   4.67E-05      
                            
  1361.7417   5.97E-05      
                            
  880.4127    7.62E-05      
                            
  1041.6349   0.00010908    
                            
  1955.9949   0.00013801    
                            
  1015.6267   0.00017407    
                            
  1087.5722   0.00017407    
                            
  1063.6231   0.00034269    
                            
  1092.5826   0.00034269    
                            
  2318.2202   0.00034269    
                            
  2536.2991   0.00034269    
                            
  2105.4972   0.00047573    
                            
  1396.5679   0.0005897     
                            
  2112.022    0.00072868    
                            
  987.5905    0.0013492     
                            
  1616.6366   0.0016465     P-FPA
                            
  2324.1475   0.0018167     C3 beta
                            
  2104.998    0.0022066     
                            
  2153.0655   0.0024291     
                            
  1450.4893   0.0026719     
                            
  2193.1036   0.0032253     C3 beta
                            
  898.4169    0.0035395     
                            
  3427.8221   0.0035395     
                            
  2163.9817   0.0046562     
                            
  1670.5947   0.0050941     
                            
  2099.1139   0.0072417     
                            
  1456.5093   0.0078632     
                            
  1418.539    0.0078923     
                            
  1630.6679   0.0078923     
                            
  2228.0362   0.0078923     
                            
  2209.0934   0.0085948     \*\*
                            
  3326.6863   0.0085948     Hb alpha
                            
  1434.5136   0.01017       
                            
  3473.7545   0.01017       Hb alpha
                            
  1432.644    0.014108      
                            
  1292.4157   0.01933       
                            
  1440.5407   0.024299      
                            
  2246.1744   0.030331      
                            
  2789.0914   0.032609      
                            
  3156.6207   0.035032      ITIH4
                            
  1276.456    0.037607      
                            
  1458.4946   0.040342      

47 peaks were significantly differential comparing NSCLC patients and healthy volunteers. Ordered by p-value. \*\* identified by Tempst *et al.*as high-molecular-weight kininogen \[[@B19]\]. Abbreviations: P-FPA: phospho-fibrinopetide A; C3 beta/f: complement C3 beta/f; Hb alpha: hemoglobin alpha; seAlb: serum albumen; ITIH4: inter-alpha-trypsin inhibitor heavy chain H4

In this secondary analysis, control subjects were unmatched for age and gender. We therefore also considered peptides that express differently in the two gender groups. For this comparison, four peptides were differential according to our criteria described above (*m/z*= 1458.495, 3215.194, 2602.305, and 2789.091). Of these four peptides, two are present in the list of 47 differential peptides in the healthy versus NSCLC comparison. Ignoring these two peptides, the signature composed of the remaining 45 peptides yielded the same accuracy, sensitivity and specificity as that of the 47-peptide signature. Literature supports that serum peptidome patterns that distinguished advanced cases of cancer from cancer-free controls were unbiased by gender and age, except for the fact that healthy subjects under 35 years could be distinguished with approximately 70% accuracy \[[@B19]\]. All participating patients in our study were 35 years or older. However, in the cancer-free control group, 4 individuals were younger than 35 years and 9 individuals older than 35 years. Comparing these two groups, two peaks met the criteria for differential (m/z = 1020.5133 and 855.0387). These two peaks did not feature in the classifying signature between the NSCLC patients and the cancer-free controls.

Peptide identification
----------------------

For structural identification of signature peptides by MS/MS, we performed an additional peptide capture on another aliquot of the sera used for profiling. Sera with highest intensity levels of signature ions were selected for MS/MS. For each eluate, a series of four spots was applied to a MALDI target plate, and candidate peaks were subjected to MS/MS in the sample spot(s) associated with the highest intensity for the pertinent peak. Seventeen peptides were positively identified by MALDI-TOF/TOF-based MS/MS analysis, see Table [8](#T8){ref-type="table"} as well as Tables [2](#T2){ref-type="table"}, [4](#T4){ref-type="table"} and [6](#T6){ref-type="table"}. See Figure [6](#F6){ref-type="fig"} for an example of an annotated MS/MS spectrum. In agreement with results by Villanueva *et al.*in other tumor types, the serum peptide signatures mainly consisted of small sets of overlapping sequences, truncated in both ends in a ladder-like fashion. See Table [8](#T8){ref-type="table"} for truncation ladder examples of Fibrinopeptide alpha, Complement C3f, Complement C3 beta and Hemoglobin alpha.

![**Tandem MS-based peptide identification**. As an example of tandem-MS generated spectra, the annotated MS/MS spectrum of precursor mass 1545.58 is displayed.](1477-5956-7-34-6){#F6}

###### 

MS/MS identification results

  ------------------------------------------------------------------------------------------------------------------------------
  **Peptide ID**   ***m/z***   **Peptide residue location**   **Peptide amino acid sequence**     **Signature(s)**
  ---------------- ----------- ------------------------------ ----------------------------------- ------------------------------
  **BK**           904.4676    381-388                        RPPGFSPF                            Time course (44)

  **P-FPA**        1616,6366   20-35                          ADS\*GEGDFLAEGGGVR                  Time course (44); PFS (13);\
                                                                                                  Response (10);\
                                                                                                  NSCLC vs. Healthy (47)

  **FPA**          1536,6906   20-35                          ADSGEGDFLAEGGGVR                    Time course (44)

  **FPA**          1350,6275   22-35                          SGEGDFLAEGGGVR                      Time course (44)

  **FPA**          1263,5958   23-35                          GEGDFLAEGGGVR                       Time course (44)

  **Glu-FPB**      1552.669    31-44                          EGVNDNEEGFFSA                       Time course (44)

  **FPB**          1129.4849   34-43                          NDNEEGFFSAR                         Time course (44)

  **C3f**          1865,0022   1304-1319                      SSKITHRIHWESASLL                    Time course (44)

  **C3f**          1777,966    1305-1319                      SKITHRIHWESASLL                     Time course (44)

  **C3f**          1690,9254   1306-1319                      KITHRIHWESASLL                      Time course (44)

  **C3 beta**      2324,1475   23-42                          SPMYSIITPNILRLESEETM                NSCLC vs. Healthy (47)

  **C3 beta**      2193,1036   23-41                          SPMYSIITPNILRLESEET                 NSCLC vs. Healthy (47)

  **Hbα**          3473,7545   2-34                           VLSPADKTNVKAAWGKVGAHAGEYGAEALERMF   NSCLC vs. Healthy (47)

  **Hbα**          3326,6863   2-33                           VLSPADKTNVKAAWGKVGAHAGEYGAEALERM    NSCLC vs. Healthy (47)

  **seAlb**        2567,3659   27-48                          HKSEVAHRFKDLGEENFKALVL              Time course (44)

  **ITIH4**        3156,6207   617-644                        NVHSGSTFFKYYLQGAKIPKPEASFSPR        Time course (44);\
                                                                                                  NSCLC vs. Healthy (47)

  **CFXIII A**     2602,3048   43-67                          AVPPNNSNAAEDDLPTVELQGVVPR           Time course (44)
  ------------------------------------------------------------------------------------------------------------------------------

Peptides were identified from the 44-peptide ion time course signature (\"time course (44)\"), the 13-peptide ion \"long PFS\" vs. \"short PFS\" signature (\"PFS (13)\"), the 10-peptide ion \"PR\" vs. \"no PR\" signature (\"Response (10)\") and the 47-peptide ion NSCLC vs. Healthy comparison (\"NSCLC vs. Healthy (47)\"). Abbreviations: FPA: fibrinopeptide A; P-FPA: phospho-fibrinopeptide A (phosphorylation site indicated by \*); FBP: fibrinopeptide B; Glu-FBP: Glu-1-Fibrinopeptide B; C3f: complement C3f; C3b: complement C3beta; Hb alpha: hemoglobin alpha; seAlb: serum albumen; ITIH4: inter-alpha-trypsin inhibitor heavy chain H4; CFXIIIA: coagulation factor XIIIA.

Discussion
==========

In this study, we investigated the use of serum peptide mass profiling by MALDI-TOF-MS coupled to bioinformatics pattern discovery to predict treatment outcome of advanced NSCLC patients treated with platinum-based therapy. Additionally, peptide patterns found in NSCLC patients were differential from those found in healthy volunteers.

To our knowledge we are the first to report on a serum peptide signature for response and survival prediction in NSCLC patients treated with cisplatin-based chemotherapy. For this study, serum samples were obtained not only pre-treatment, but also during treatment and after completion of treatment, whereas serum proteomics studies typically focus on pre-treatment samples only. In a study by Taguchi *et al.*, a predictive MALDI-TOF-MS-based peptide algorithm for \"good\" or \"poor\" clinical outcome upon epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI) therapy was established \[[@B20]\]. However, in this study none of the peptides corresponding to the classifying *m/z*features were identified.

In our study, for the short PFS versus long PFS classification, we achieved 82% accuracy with a 6-peptide-signature. A longer overall survival of the patients classified as \"long PFS\" and a shorter overall survival of the patients classified as \"short PFS\" was observed. Interestingly, performance of the signature was improved upon inclusion of 7 differential time-course peptides, the combined 13 peptide-ion signature achieving 86% accuracy. In this regard, it has been previously reported that histological response of locally advanced rectal cancer to radiochemotherapy could be predicted by SELDI-TOF-MS-based profiling and comparison of serum samples collected pre-treatment and during treatment \[[@B21]\].

For partial responders versus non-partial responders we achieved 89% accuracy with a 5-peptide signature. Inclusion of differential time-course peptides did not improve performance of this signature. Longer duration of progression-free survival was strongly associated with tumour response as seven out of eleven patients in our study with long PFS also had a partial tumour response upon treatment, compared to one out of eleven patients in the short PFS group. This suggests that the survival signature is predictive of therapy-outcome rather than prognostic. As the Kaplan-Meier analysis showed, prediction of response using the 5- or 10-peptide signatures was significantly associated with a longer median PFS of those patients, but this did not reach significance for overall survival.

In several MALDI serum peptide profiling studies involving other solid tumour types (bladder, breast, prostate, thyroid) by Villanueva *et al.*, methodologically comparable to our study, the hypothesis was put forward that cancer-type specific changes in exopeptidase activities yield surrogate biomarkers, reflected in the differential abundance of cleavage products of common serum substrate proteins \[[@B19],[@B22]\]. The changes in exopeptidase activity were superimposed on the proteolytic events of the complement degradation and *ex vivo*coagulation pathways and therefore serum-specific. Regulated peptides at *m/z*1690.925, 1777.966 and 1865.002 correspond to those identified in our study at 1690.90, 1777.94 and 1864.95, respectively, previously identified by MALDI-TOF-TOF-based MS/MS analysis as Complement C3f. The peptide at 2209.093 corresponds to the one we detected at 2209.08, previously identified as HMW Kininogen \[[@B19]\].

We show that in NSCLC, the identified differential serum peptides changing in abundance over time and those distinguishing NSCLC patients from cancer-free control subjects consisted of truncated sequence clusters. The identified peptides were derived from naturally occurring serum peptides and protein precursors, and therefore not likely to be tumor-derived, thus supporting the exoprotease hypothesis. For the predictive algorithms, it is important to realize that these might be specific for the treatment combination of bortezomib, cisplatin and gemcitabine and may not apply to other treatment regimens. For this exploratory analysis, we did not perform a power calculation beforehand as we did not know the biological variation in our patient groups, nor the number of peaks we would measure as well as other variables. We only knew the technical variation. It was therefore our approach to collect as many samples as we could accommodate. It is crucial to validate and adjust the established signatures with an independent cohort in a sufficiently powered follow-up study. Additionally, since only one report excludes an age and gender bias for a cancer-specific serum peptide signature, it is advisable to include matched cancer-free control groups for the establishment of cancer-specific peptide patterns.

Conclusion
==========

Ideally, serum peptide mass profiling can be used to identify the therapeutic agents to which the tumour is sensitive, enabling personalized medicine. The method employed here requires readily accessible, non-invasively obtainable patient samples, is high-throughput and cost-efficient, all together important requirements for a screening platform as well as routine clinical use. The biggest challenge might very well remain lack of reproducibility related to sample collection in the clinic. In particular, maintaining a constant and precise clotting time is often difficult in clinical practice. Potentially, after initial discovery of classifying algorithms, functional proteomics tests will facilitate clinical implementation \[[@B23]\].

Methods
=======

Patients and serum preparation
------------------------------

The training set included 27 patients with NSCLC who were treated with chemotherapy and bortezomib as well as 13 healthy volunteers \[[@B12]\]. All patients were treated with cisplatin 70 mg/m^2^day 1 and gemcitabine 1,000 mg/m^2^days 1 and 8, every 21 days for up to 6 cycles. Fifteen patients were treated with bortezomib on days 1 and 8 of every cycle (ten patients at 1.0 mg/m^2^and five patients at 1.3 mg/m^2^). Twelve patients were treated with bortezomib on days 1,4,8 and 11 of every cycle (one patient at 0.7 mg/m^2^and eleven patients at 1.0 mg/m^2^). There was no indication of superior clinical activity of any schedule of bortezomib in combination with cisplatin and gemcitabine \[[@B12]\]. Blood samples were obtained in BD Vacutainer glass \"red-top\" tubes (Becton Dickinson, Franklin Lakes, NJ), allowed to clot for 1 hour, and then centrifuged at 1500 g for 10 minutes. Sera were stored in polypropylene cryovials (Nunc; Roskilde, Denmark) at -80°C. Studies were performed after obtaining patient consent and under protocols approved by the institutional review board.

Serum sample processing and mass spectrometry
---------------------------------------------

Samples were processed in randomized order, along with control samples to check consistency in each experiment. Magnetic Dynabeads^®^RPC 18 (Invitrogen, San Diego, CA) were used for serum peptide capture using the KingFischer96 platform, as described previously \[[@B11]\]. Briefly, in a 96-well format, magnetic beads were washed and equilibrated twice in 200 μl 200 mM NaCl/0.1% TFA, transferred to a mix of 20 μl serum sample and 2 volumes of 0.2% n-octyl glucoside/0.5% TFA (premixed for 5 min), incubated for 2 min, washed thrice with 0.1% TFA, and eluted for 2 min with 40 μl 50% acetonitrile.

Processed samples (1.5 μl eluate) were mixed with 2 volumes α-cyano-4-hydroxycinnamic acid matrix (6.2 mg/ml in 56% acetonitrile, 36% methanol; Agilent, Santa Clara, CA) and 0.7 μl of this mix was spotted on a MALDI plate. A 4800 MALDI-TOF/TOF mass spectrometer (Applied Biosystems, Foster City, CA) was used to record with 5000 shots per spectrum (reflectron mode) serum peptide profiles in the mass range of *m/z*800-4000 \[[@B11]\]. Internal calibration was used using a list of exact masses for fibrinogen α/fibrinopeptide A peptides as major components of serum samples. For MS/MS analysis, stepwise attempts of 5000 shots at a time generated spectra for identification by the Mascot search engine or manual identification. For Mascot searches, the SwissProt database (release 54.7) was used at a mass window of 10 ppm for MS and a 1-Da tolerance for MS/MS. Final scores were obtained by narrowing down the window. For manual identification, spectra were compared with theoretical peptide fragments of reported candidate proteins \[[@B19]\]. Fragments having a predicted mass differing less than 10 ppm from the mass of any of the 87 significantly regulated peaks from our profiling study were identified using FindPept <http://www.expasy.ch>\[[@B19]\]. Fragmentation patterns were predicted using MS-Product <http://prospector.ucsf.edu/prospector/mshome.htm>, requiring that at least 3 prominent peaks in the experimental spectrum should match b or y ions from the theoretical table.

Signal processing
-----------------

Spectra were pre-processed using MarkerView, version 1.2 (Applied Biosystems) with a mass tolerance of 200.0 ppm and minimum intensity at 100.0 units. Total signal intensity of all peptide peaks was used for normalization.

Statistical analysis
--------------------

Feature selection was performed using the Mann-Whitney U test on each peptide detected in the pre-processing step. We used a common threshold of 5% for the p-value. As p-values were not adjusted for multiple testing, we took additional measures to guard from false discovery. To reduce differences due to noise, each peptide was subjected to intensity filtering, requiring that the median intensity of at least one group must be greater than 80 units and the fold change of the median intensities of the two groups must be greater than 1.5. For time course analysis of the three time points, we treated the problem as three binary comparisons. For each comparison, a paired, two-sided signed rank test was carried out. Each peptide was again subjected to intensity filtering. The results of the three comparisons were merged where the significance level of each peptide was the minimum of the three p-values. Similarly, we analyzed dynamic peptide profiles (time-course), using the group information, in order to identify peptides of which the intensity level changes differently between different clinical groups. Finally, support vector machine with the Gaussian kernel was used to construct classification models. A two dimensional grid search was carried out to set model parameters using the leave-one-out cross-validation (LOOCV) measure. Analogously to Villanueva et al. \[[@B19]\], we used a statistical test for feature selection. This procedure is based on class label, thus bias might be introduced. Nevertheless, this strategy was shown to be effective in previous studies \[[@B19],[@B22]\]. Median duration of progression-free and overall survival was calculated using the Kaplan-Meier method; p-values according to the log-rank test (SPSS Statistics17.0, SPSS Inc., Chicago, IL).
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